- Home
- AMGN vs HOOD Comparison
AMGN vs HOOD Comparison
Compare AMGN & HOOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- HOOD
- Stock Information
- Founded
- AMGN 1980
- HOOD 2013
- Country
- AMGN United States
- HOOD United States
- Employees
- AMGN N/A
- HOOD N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- HOOD Computer Software: Prepackaged Software
- Sector
- AMGN Health Care
- HOOD Technology
- Exchange
- AMGN Nasdaq
- HOOD Nasdaq
- Market Cap
- AMGN 150.8B
- HOOD 127.2B
- IPO Year
- AMGN N/A
- HOOD 2021
- Fundamental
- Price
- AMGN $295.58
- HOOD $137.14
- Analyst Decision
- AMGN Hold
- HOOD Buy
- Analyst Count
- AMGN 15
- HOOD 23
- Target Price
- AMGN $313.57
- HOOD $112.43
- AVG Volume (30 Days)
- AMGN 2.1M
- HOOD 24.8M
- Earning Date
- AMGN 11-04-2025
- HOOD 11-05-2025
- Dividend Yield
- AMGN 3.21%
- HOOD N/A
- EPS Growth
- AMGN 110.88
- HOOD 513.62
- EPS
- AMGN 12.23
- HOOD 1.96
- Revenue
- AMGN $34,917,000,000.00
- HOOD $3,567,000,000.00
- Revenue This Year
- AMGN $8.82
- HOOD $47.78
- Revenue Next Year
- AMGN $1.84
- HOOD $20.55
- P/E Ratio
- AMGN $24.26
- HOOD $74.85
- Revenue Growth
- AMGN 12.88
- HOOD 59.38
- 52 Week Low
- AMGN $253.30
- HOOD $23.54
- 52 Week High
- AMGN $335.88
- HOOD $153.86
- Technical
- Relative Strength Index (RSI)
- AMGN 54.10
- HOOD 50.30
- Support Level
- AMGN $288.26
- HOOD $137.25
- Resistance Level
- AMGN $301.00
- HOOD $150.46
- Average True Range (ATR)
- AMGN 5.96
- HOOD 6.45
- MACD
- AMGN -0.33
- HOOD -0.42
- Stochastic Oscillator
- AMGN 46.95
- HOOD 54.95
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About HOOD Robinhood Markets Inc.
Robinhood Markets Inc is creating a modern financial services platform. It designs its own products and services and delivers them through a single, app-based cloud platform supported by proprietary technology. Its vertically integrated platform has enabled the introduction of new products and services such as cryptocurrency trading, dividend reinvestment, fraud detection, derivatives, fractional shares, recurring investments, and others.